In late 1997 - early 1998 a novel trinuclear platinum compound, BBR3464, will enter Phase 1 clinical trials, the first genuinely new platinum agent not based on the classical cisplatin structure to do so. The profile of preclinical activity mirrors its unique structure and is characterized by activity in human tumor (e.g. ovarian) xenografts resistant to cisplatin and alkylating agents; a high activity in a broad spectrum of human tumors commonly insensitive to chemotherapeutic intervention (e.g. non-small-cell lung, gastric) and characterized as p53-mutant. The p53 protein is recognized as playing a critical role in cellular response to drug-induced DNA damage. Loss of normal p53 function can lead to intrinsic drug resistance as a result of reduced cell ability to engage an apoptotic response. Thus, a clinical drug acting independently of the p53 pathway can offer outstanding clinical promise for chemotherapy in over 50 percent of solid human tumors with defective p53. This proposal will explore the hypothesis that these new agents, in comparison to other clinical agents, exert their cytotoxicity and antitumor activity in a p53-independent manner through differential repair traceable to a unique array of DNA adducts, different in scope and effect to any of the DNA-damaging currently agents used in the clinic. This proposal will therefore delineate the types of adducts formed and begin to examine the structural consequences thereof with respect to protein recognition and DNA repair.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Metallobiochemistry Study Section (BMT)
Program Officer
Beisler, John A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Schools of Arts and Sciences
United States
Zip Code
Farrell, Nicholas P; Gorle, Anil K; Peterson, Erica J et al. (2018) Metalloglycomics. Met Ions Life Sci 18:
Brabec, Viktor; Kasparkova, Jana; Menon, Vijay et al. (2018) Polynuclear Platinum Complexes. Structural Diversity and DNA Binding. Met Ions Life Sci 18:
Malina, Jaroslav; Farrell, Nicholas P; Brabec, Viktor (2018) Substitution-Inert Polynuclear Platinum Complexes That Inhibit the Activity of DNA Polymerase in Triplex-Forming Templates. Angew Chem Int Ed Engl 57:8535-8539
Tsotsoros, S D; Lutz, P B; Daniel, A G et al. (2017) Enhancement of the physicochemical properties of [Pt(dien)(nucleobase)]2+ for HIVNCp7 targeting. Chem Sci 8:1269-1281
Peterson, Erica J; Daniel, A Gerard; Katner, Samantha J et al. (2017) Antiangiogenic platinum through glycan targeting. Chem Sci 8:241-252
Brabec, Viktor; Kasparkova, Jana; Kostrhunova, Hana et al. (2016) Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Sci Rep 6:28474
Stukova, Marina; Hall, Matthew D; Tsotsoros, Samantha D et al. (2015) Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem 149:45-8
Qu, Y; Kipping, R G; Farrell, N P (2015) Solution studies on DNA interactions of substitution-inert platinum complexes mediated via the phosphate clamp. Dalton Trans 44:3563-72
Farrell, N P (2015) Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets. Chem Soc Rev 44:8773-85
Peterson, Erica J; Menon, Vijay R; Gatti, Laura et al. (2015) Nucleolar targeting by platinum: p53-independent apoptosis follows rRNA inhibition, cell-cycle arrest, and DNA compaction. Mol Pharm 12:287-97

Showing the most recent 10 out of 70 publications